Company Filing History:
Years Active: 2016
Title: Exploring the Innovations of Sean E Brynjelsen
Introduction
Sean E Brynjelsen, located in Barrington, Illinois, is an innovative inventor making strides in the medical field. With a focus on enhancing the stability of pharmaceuticals, Brynjelsen has made significant contributions to the formulation of injectable medications. His work represents the intersection of chemistry and healthcare, aiming to improve patient outcomes.
Latest Patents
Sean E Brynjelsen holds a patent for a stable pentobarbital formulation. This invention is particularly notable for its greater stability and fewer impurities. The formulation consists of an aqueous solution containing 50 mg/mL pentobarbital sodium, 50% glycol, and 10% alcohol, with a target pH of 9.4. This advancement in pentobarbital formulation is crucial for ensuring reliability and efficacy in its medical applications.
Career Highlights
Currently, Sean E Brynjelsen is employed at Akorn, Inc., a company renowned for its work in specialty pharmaceuticals. His role in developing stable formulations marks a significant accomplishment in his career, contributing to the company's reputation for quality and innovation in the pharmaceutical industry.
Collaborations
In his work, Sean collaborates with his coworker, Biswajit Pati. Their partnership reflects a commitment to pushing the boundaries of pharmaceutical chemistry, aiming to enhance existing formulations and create new solutions for medical practitioners and patients alike.
Conclusion
Sean E Brynjelsen exemplifies the spirit of innovation in the field of pharmaceuticals. Through his patent for a stable pentobarbital formulation, he demonstrates the potential for improved medication stability and safety. His work at Akorn, Inc., alongside dedicated colleagues, positions him as a key figure in the ongoing development of effective and dependable pharmaceutical solutions.